{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:44:44Z","timestamp":1785552284462,"version":"3.56.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ejso.2019.01.221","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T07:37:56Z","timestamp":1549006676000},"page":"1246-1252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Clear cell renal cell carcinoma bone metastasis: What should be considered in prognostic evaluation"],"prefix":"10.1016","volume":"45","author":[{"given":"Zixiong","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2019.01.221_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2017.06.060","article-title":"Metastatic renal cell carcinoma: patterns and predictors of metastases\u2014a contemporary population-based series","volume":"35","author":"Chandrasekar","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ejso.2019.01.221_bib2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bone.2010.09.008","article-title":"Skeletal complications and survival in renal cancer patients with bone metastases","volume":"48","author":"Woodward","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.ejso.2019.01.221_bib3","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/annonc\/mdr362","article-title":"Distribution of metastatic sites in renal cell carcinoma: a population-based analysis","volume":"23","author":"Bianchi","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2019.01.221_bib4","first-page":"391","article-title":"Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage","volume":"188","author":"Keegan","year":"2012","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ejso.2019.01.221_bib5","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1111\/j.1464-410X.2008.08259.x","article-title":"A\u00a0critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study","volume":"103","author":"Capitanio","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.ejso.2019.01.221_bib6","first-page":"1309","article-title":"Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma","volume":"183","author":"Leibovich","year":"2010","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ejso.2019.01.221_bib7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/01.blo.0000149820.65137.b4","article-title":"Solitary bony metastasis from renal cell carcinoma: significance of surgical treatment","volume":"431","author":"Fuchs","year":"2005","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ejso.2019.01.221_bib8","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamaoncol.2016.6770","article-title":"Effect of radiotherapy on painful bone metastases: a secondary analysis of the NCIC clinical trials group symptom control trial SC. 23","volume":"3","author":"McDonald","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejso.2019.01.221_bib9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.eururo.2017.11.016","article-title":"Updated European Association of Urology guidelines recommendations for the treatment of first-line metastatic clear cell renal cancer","volume":"73","author":"Powles","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejso.2019.01.221_bib10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.5489\/cuaj.1760","article-title":"Contemporary incidence and mortality rates of kidney cancer in the United States","volume":"8","author":"Gandaglia","year":"2014","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.ejso.2019.01.221_bib11","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.urology.2015.05.008","article-title":"Trends in metastatic kidney cancer survival from the cytokine to the targeted therapy era","volume":"86","author":"Macleod","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.ejso.2019.01.221_bib12","first-page":"379","article-title":"The skeletal metastatic complications of renal cellcarcinoma","volume":"19","author":"Zekri","year":"2001","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ejso.2019.01.221_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2019.01.221_bib14","first-page":"642","article-title":"Expression of intermediate filament proteins in subtypes of renal cell carcinomas and in renal oncocytomas. Distinction of two classes of renal cell tumors","volume":"56","author":"Pitz","year":"1987","journal-title":"Lab Invest"},{"key":"10.1016\/j.ejso.2019.01.221_bib15","first-page":"1092","article-title":"Germ-line mutations in the von Hippel\u2013Lindau tumor-suppressor gene are similar to somatic von Hippel\u2013Lindau aberrations in sporadic renal cell carcinoma","volume":"55","author":"Whaley","year":"1994","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ejso.2019.01.221_bib16","first-page":"825","article-title":"Proximal renal tubular surface membrane antigens identified in primary and metastatic renal cell carcinomas","volume":"110","author":"Yoshida","year":"1986","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ejso.2019.01.221_bib17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00000478-200002000-00006","article-title":"Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms","volume":"24","author":"Avery","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejso.2019.01.221_bib18","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2559.1985.tb02859.x","article-title":"The distribution of epithelial membrane antigen in the kidney and its tumours","volume":"9","author":"Fleming","year":"1985","journal-title":"Histopathology"},{"key":"10.1016\/j.ejso.2019.01.221_bib19","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1158\/1078-0432.CCR-18-0252","article-title":"Identification and validation of radiographic enhancement for reliable differentiation of CD117 (+) benign renal oncocytoma and chromophobe renal cell carcinoma","volume":"24","author":"Amin","year":"2018","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejso.2019.01.221_bib20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/jclinpath-2014-202259","article-title":"PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma?","volume":"68","author":"Barr","year":"2015","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.ejso.2019.01.221_bib21","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/PAI.0000000000000004","article-title":"Immunohistochemical distinction of renal cell carcinoma from other carcinomas with clear-cell histomorphology: utility of CD10 and CA-125 in addition to PAX-2, PAX-8, RCCma, and adipophilin","volume":"22","author":"Mentrikoski","year":"2014","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.ejso.2019.01.221_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083026","article-title":"Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey","volume":"8","author":"Santini","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejso.2019.01.221_bib23","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ctrv.2011.06.011","article-title":"Skeletal metastasis in renal cell carcinoma: current and future management options","volume":"38","author":"Wood","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejso.2019.01.221_bib24","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.eururo.2015.01.005","article-title":"EAU guidelines on renal cell carcinoma: 2014 update","volume":"67","author":"Ljungberg","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejso.2019.01.221_bib25","first-page":"e577","article-title":"Treatments, outcomes and validity of prognostic scores in patients with sarcomatoid renal cellcarcinoma: a twenty years' single institution experience","volume":"16","author":"Korenbaum","year":"2017","journal-title":"Clin Genitourin Canc"},{"key":"10.1016\/j.ejso.2019.01.221_bib26","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/s41467-017-00701-6","article-title":"Androgen receptor increases hematogenous metastasis yet decreases lymphatic metastasis of renal cell carcinoma","volume":"8","author":"Huang","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejso.2019.01.221_bib27","article-title":"An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma","volume":"1","author":"Gr\u00fcnwald","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ejso.2019.01.221_bib28","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/bjc.2015.352","article-title":"RANK\/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs","volume":"113","author":"Beuselinck","year":"2015","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejso.2019.01.221_bib29","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2019.01.221_bib30","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/annonc\/mdq554","article-title":"Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib","volume":"22","author":"Beuselinck","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2019.01.221_bib31","first-page":"802","article-title":"Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy","volume":"9","author":"Bui","year":"2003","journal-title":"Clin Canc Res"},{"issue":"1","key":"10.1016\/j.ejso.2019.01.221_bib32","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3892\/ol.2012.1001","article-title":"Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma","volume":"5","author":"Takacova","year":"2013","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ejso.2019.01.221_bib33","first-page":"1","article-title":"Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?","volume":"34","author":"Santoni","year":"2015","journal-title":"J\u00a0Exp Clin Canc Res"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798319302471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798319302471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:29:14Z","timestamp":1760059754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798319302471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0748798319302471"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2019.01.221","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clear cell renal cell carcinoma bone metastasis: What should be considered in prognostic evaluation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2019.01.221","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}